USA — Terumo Blood and Cell Technologies has received approval from the US Food and Drug Administration (FDA) and launched its IMUGARD WB platelet pooling set.
This new medical technology extends the shelf life of whole blood-derived platelets from five to seven days, while providing an alternative source of supply to meet increasing demand for platelets due to a shortage of blood donors.
IMUGARD is the first platelet pooling set approved for seven-day storage in the US, offering greater flexibility in platelet supply.
Terumo Blood and Cell Technologies’ general manager of global blood solutions, Chetan Makam, said that IMUGARD allows U.S. blood centers to utilize platelets from whole blood donations to increase the number of platelets available for transfusion.
The extended shelf-life also enables blood centers to better manage their supply and reduce waste, and IMUGARD provides an alternative to retrieve platelets from whole blood donations.
Platelets are essential in helping to form blood clots to slow or stop bleeding and heal wounds and are used to treat patients undergoing chemotherapy, organ transplants, and bone marrow transplants.
Terumo Blood and Cell Technologies provides products, software, and services to customers including hospitals, therapeutic apheresis clinics, researchers, and private medical practices.
The blood collection market has recently seen several developments, including notable partnerships and product launches by key players.
In 2021, Terumo Blood and Cell Technologies teamed up with CSL Plasma to introduce a new plasma collection platform.
Meanwhile, Greiner Bio-One, another major player in the market, launched the MiniCollect PIXIE Heel Incision Safety Lancet to expand its product line and provide a new safety lancet option for individuals requiring heel incisions.
Additionally, Quest Diagnostics Incorporated acquired Nationwide Laboratory Services, a Boca Raton-based company, to promote better health in South Florida communities.
The global blood collection market was valued at US$4.8 billion in 2021 and is projected to reach US$7.9 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031, as per Allied Markets Research.
The blood collection market size is expected to grow due to various factors such as an increase in the number of surgical procedures performed, a rise in the prevalence of chronic diseases like blood cancer, and an increase in government expenditure on healthcare.
The market is also driven by the prevalence of infectious and non-communicable diseases, along with the approval of technologically advanced products.
The projected considerable growth of the blood collection market during the forecast period is a promising sign for the healthcare industry.
Blood collection is a vital procedure in the medical field as it is used to obtain blood samples from patients for laboratory testing.